Shares of Alkermes Plc (NASDAQ: ALKS) skyrocketed 16% in regular trading hours on Wednesday after the biopharmaceutical company said that its stage-2 clinical trial on the unbranded drug called ALKS 5461 showed that it was effective in treating patients suffering from major depressive disorder (MDD). In a statement, the Company said that study conducted among [...]
Recent Comments